Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A pivotal Phase 2 study of PRGN-2012 for the treatment of recurrent respiratory papillomatosis (RRP)

Next Previous
Trial Profile

A pivotal Phase 2 study of PRGN-2012 for the treatment of recurrent respiratory papillomatosis (RRP)

Status: Planning
Phase of Trial: Phase II

Latest Information Update: 14 May 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Most Recent Events

  • 14 May 2024 New trial record
  • 08 May 2024 According to Precigen media release, The Company will host a conference call on Monday, June 3, 2024 to discuss in detail the pivotal Phase 2 study data of PRGN-2012 for the treatment of recurrent respiratory papillomatosis (RRP) presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting. Additional details for the June 3rd conference call will be announced at a later date.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top